|
1
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous
Leukemia, V.2.[DB/OL].(2007-10-25). 2008.
|
|
2
|
Druker BJ and Lee SJ: Chronic myelogenous
leukemia. Cancer: Principles and Practice of Oncology. 2007.
|
|
3
|
Incidence survey of leukemia in China, .
Chinese Epidemiologic Study Group of Leukemia and Aplastic Anemia.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 14:12–19. 1992.(In Chinese).
PubMed/NCBI
|
|
4
|
Goldman JM and Melo JV: Chronic myeloid
leukemia-advances in biology and new approaches to treatment. N
Engl J Med. 349:1451–1464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McWhirter JR and Wang JY: An actin-binding
function contributes to transformation by the Bcr-Abl oncoprotein
of Philadelphia chromosome-positive human leukemias. EMBO J.
12:1533–1546. 1993.PubMed/NCBI
|
|
6
|
van Etten RA, Jackson PK, Baltimore D,
Sanders MC, Matsudaira PT and Janmey PA: The COOH terminus of the
c-Abl tyrosine kinase contains distinct F- and G-actin binding
domains with bundling activity. J Cell Biol. 124:325–340. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Foroni L, Gerrard G, Nna E, Khorashad JS,
Stevens D, Swale B, Milojkovic D, Reid A, Goldman J and Marin D:
Technical aspects and clinical applications of measuring BCR-ABL1
transcripts number in chronic myeloid leukemia. Am J Hematol.
84:517–522. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hackanson B and Daskalakis M: Decitabine.
Recent Results Cancer Res. 201:269–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kantarjian HM, O'Brien SM, Keating M,
Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D and
Talpaz M: Results of decitabine therapy in the accelerated and
blastic phases of chronic myelogenous leukemia. Leukemia.
11:1617–1620. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sacchi S, Kantarjian HM, O'Brien S, Cortes
J, Rios MB, Giles FJ, Beran M, Koller CA and Keating MJ: Chronic
myelogenous leukemia in nonlymphoidblastic phase: Analysis of the
results of first salvage therapy with three different treatment
approaches for 162 patients. Cancer. 86:2632–2641. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kantarjian HM, O'Brien S, Cortes J, Giles
FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff
M, et al: Results of decitabine (5-aza-2-deoxycytidine) therapy in
130 patients with chronic myelogenousleukemia. Cancer. 98:522–528.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Issa JP, Garcia-Manero G, Giles FJ,
Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS,
Cortes J and Kantarjian HM: Phase 1 study of low-dose prolonged
exposure schedules of the hypomethylating agent
5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies.
Blood. 103:1635–1640. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Issa JP, Gharibyan V, Cortes J, Jelinek J,
Morris G, Verstovsek S, Talpaz M, Garcia-Manero G and Kantarjian
HM: Phase II study of low-dose decitabine in patients with chronic
myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol.
23:3948–3956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu C, Sun M, Liu L and Zhou GW: The
function of the protein tyrosine phosphatase SHP-1 in cancer. Gene.
306:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oka T, Yoshino T, Hayashi K, Ohara N,
Nakanishi T, Yamaa Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, et
al: Reduction of hematopoietic cell specific tyrosine phosphatase
SHP-1 gene expression in natural killer cell lymphoma and various
types of lymphom as/leukemia. Combination analysic with cDNA
expression array and tissue micrearray. Am J Patho. 159:1495–1505.
2001. View Article : Google Scholar
|
|
16
|
Amin HM, Hoshino K, Yang H, Lin Q, Lai R
and Garcia-Manero G: Decreased expression level of SH2
domain-containing protein tyrosine phosphatase-1 (Shp1) is
associated with progression of chronic myeloid leukaemia. J Pathol.
212:402–410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Q, Wang HY, Marzec M, Raghunath PN,
Nagasawa T and Wasik MA: STAT3- and DNA methyltransferase
1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor
suppressor gene in malignant T lymphocyte. Proc Natl Acad Sci USA.
102:pp. 6948–6953. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uhm KO, Lee ES, Lee YM, Park JS, Kim SJ,
Kim BS, Kim HS and Park SH: Differential methylation pattern of
ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic
myeloid leukemia. J Korean Med Sci. 24:493–497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chim CS, Fung TK, Cheung WC, Liang R and
Kwong YL: SOCS1 and SHP1 hypermethylation in multiple myeloma:
Implications for epigenetic activation of the Jak/STAT pathway.
Blood. 103:4630–4635. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim JH, Choi YD, Lee JS, Lee JH, Nam JH
and Choi C: Assessment of DNA methylation for the detection of
cervical neoplasiain liquid-based cytology specimens. Gynecol
Oncol. 116:99–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu SB, Liu XH, Li BH, Zhang Y, Yuan J,
Yuan Q, Li PD, Yang XZ, Li F and Zhang WJ: DNA methylation
regulates constitutive expression of Stat6 regulatory genes SOCS-1
and SHP-1 in colon cancer cells. J Cancer Res Clin Oncol.
135:1791–1798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liedtke M, Pandey P, Kumar S, Kharbanda S
and Kufe D: Regulation of Bcr-Abl-induced SAP kinase activity and
transformation by the SHPTP1 protein tyrosine phosphatase.
Oncogene. 17:1889–1892. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cramer K, Nieborowska-Skorska M, Koptyra
M, Slupianek A, Penserga ET, Eaves CJ, Aulitzky W and Skorski T:
BCR/ABL and other kinases from chronic myeloproliferative disorders
stimulate single-strand annealing, an unfaithful DNA double-strand
break repair. Cancer Res. 68:6884–6888. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oka T, Ouchida M, Koyama M, Ogama Y,
Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, et
al: Gene silencing of the tyrosine phosphatase SHP1 gene by
aberrant methylation in leukemias/lymphomas. Cancer Res.
62:6390–6394. 2002.PubMed/NCBI
|
|
27
|
Soriano AF, Helfrich B, Chan DC, Heasley
LE, Bunn PA Jr and Chou TC: Synergistic effects of new
chemopreventive agents and conventional cytotoxic agents against
human lung cancer cell lines. Cancer Res. 59:6178–6184.
1999.PubMed/NCBI
|
|
28
|
Lozzio CB and Lozzio BB: Human chronic
myelogenous leukemia cell-line with positive Philadelphia
chromosome. Blood. 45:321–334. 1975.PubMed/NCBI
|
|
29
|
Momparler RL, Côté S and Eliopoulos N:
Pharmacological approach for optimization of the dose schedule of
5-Aza-2-deoxycytidine (Decitabine) for the therapy of leukemia.
Leukemia. 11 Suppl 1:S1–S6. 1997.PubMed/NCBI
|
|
30
|
Savage DG and Antman KH: Imatinib
mesylate-a new oral targeted therapy. N Eng J Med. 346:683–693.
2002. View Article : Google Scholar
|
|
31
|
Tonks NK and Neel BG: From form to
function: Signaling by protein tyrosine phosphatases. Cell.
87:365–368. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bruecher-Encke B, Griffin JD, Neel BG and
Lorenz U: Role of the tyrosine phosphatase SHP-1 in K562 cell
differentiation. Leukemia. 15:1424–1432. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Esposito N, Colavita I, Quintarelli C,
Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T,
Hughes TP, et al: SHP-1 expression accounts for resistance to
imatinib treatment in Philadelphia chromosome-positive cells
derived from patients with chronic myeloid leukemia. Blood.
118:3634–3644. 2011. View Article : Google Scholar : PubMed/NCBI
|
